The UK Health Security Agency (UKHSA) confirmed last week the detection of a single case of the mpox virus variant Clade 1b in London. Following this initial report, two additional cases have been identified among household contacts of the first patient. All three individuals are currently receiving specialized care at Guy’s and St Thomas’ NHS Foundation Trust in London.
Despite the emergence of these cases, the UKHSA has assessed that the risk to the general UK population remains low. “Extensive planning has been underway to ensure healthcare professionals are equipped and prepared to respond to any further confirmed cases,” the agency stated.
Professor Susan Hopkins, the UKHSA’s chief medical adviser, noted that mpox is highly infectious in household settings, making it unsurprising to see further cases arise within the same household. “The overall risk to the UK population remains low. We are working with partners to ensure all contacts of the cases are identified and contacted to reduce the risk of further spread,” she added.
The initial case reported in London involved a traveler who had recently returned from a holiday in Africa. This individual began experiencing flu-like symptoms more than 24 hours after arriving back in the UK, followed by the development of a rash that worsened over the subsequent days.
The UKHSA is actively monitoring contacts of all three confirmed cases and will offer testing and vaccinations as necessary to mitigate the potential spread of the virus.
Understanding Mpox
Common symptoms of mpox include a skin rash or pus-filled lesions, which can last between two to four weeks, alongside flu-like symptoms such as fever, headaches, muscle aches, back pain, low energy, and swollen lymph nodes. The Clade 1b strain of mpox is primarily transmitted through close physical contact, contact with infected animals, or sexual transmission.
In anticipation of further cases, the UK has a stock of mpox vaccines, and last month, officials announced plans to procure additional doses to support a routine immunization program.
As the situation develops, health authorities remain vigilant, reinforcing the importance of prompt reporting and effective communication in managing public health risks associated with the mpox virus.
